altSonflex1-2-3 Dose C

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Diarrhoea

Phase 1

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants

CompletedNCT05073003

GlaxoSmithKlineDiarrhoea

Start: 2021-10-06End: 2025-06-24Updated: 2025-12-04

Phase 2

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

CompletedNCT06663436

GlaxoSmithKlineDiarrhoea

Start: 2024-11-13End: 2025-10-21Updated: 2026-01-30

Related Papers

Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens <i>Shigella</i> Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study

The Journal of Infectious Diseases2024-06-1020 citations

Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine.

2024-03-087 citations